Last updated: 2026-09-08 17:23:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Taysha Gene Therapies, Inc. (TSHA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $5,49, with a market capitalization of $1,82B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,71 to $7,30. This page covers its latest market performance, valuation, price trends and company information.
$1,82B | |
$5,57 | |
$33,35 | |
$0,50 | |
$5,60 | |
595,18K | |
3,14M | |
-- | |
$7,30 | |
$2,71 | |
-- | |
-- |
Taysha Gene Therapies, Inc. (TSHA) is currently trading at $5,49 as of 2026-09-08 17:21:00, down 2,05% ($0,11) from the previous close of $5,60
During today's regular trading session, TSHA has traded between $0,50 and $33,35, with a trading volume of 595,18K shares. The current price is near the lower end of today's range.
Over the past seven days, Taysha Gene Therapies, Inc. (TSHA) moved from $5,96 to $5,49, representing a decline of 7,97% ($0,47).
The stock traded between $5,41 and $6,09 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2,01 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 60,5%
TSHA is currently trading at $5,49, placing it 60,5% of the way from its 52-week low of $2,71 to its 52-week high of $7,30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 99 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Taysha Gene Therapies, Inc. (TSHA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.